Onkure Therapeutics Inc. has described phosphatidylinositol 3-kinase α (PI3Kα) (H1047R mutant) inhibitors reported to be useful for the treatment of cancer, congenital lipomatous overgrowth, vascular ...

Laekna Pharmaceutical Ningbo Co. Ltd. has synthesized phosphatidylinositol 3-kinase α (PI3Kα) and its mutant (H1047R) inhibitors reported to be useful for the treatment of breast cancer.

PI3Kα mutations are prevalent in patients with breast, colorectal, lung, endometrial, and numerous other cancers. However, the first-generation drugs targeting PI3Kα inhibit the wild-type and mutant ...

SNV4818 is a potentially best-in-class pan-mutant-selective PI3Kα inhibitor that may effectively cover kinase (H), helical domain (E), and other PI3Kα mutations clinically. This marks the second ...

OnKure Therapeutics provided an update on its ongoing clinical trials and financial results for 2024, highlighting significant progress in their PI3Kα inhibitor programs. The PIKture-01 trial is ...

While current FDA-approved PI3Kα inhibitors, such as alpelisib, have demonstrated success in treating hormone receptor-positive (HR+) and HER2-negative (HER2-) breast cancer, their clinical ...

The firm highlighted OnKure Therapeutics as a clinical-stage company focused on precision oncology, specifically developing targeted PI3Kα inhibitors for the treatment of breast cancer and other ...

InitiationofPhase3ReDiscover-2trialofRLY-2608+fulvestrantanticipatedinthemiddleof2025in PI3Kα-mutated,CDK4/6pre-treated,HR+/HER2-metastaticbreastcancer ...

"We are thrilled to present the first clinical data for our lead program, OKI-219, which is the only highly selective PI3Kα H1047R inhibitor molecule in the clinic,” said Nicholas Saccomano, Ph.D., ...

PI3Kα mutations are prevalent in patients with breast, colorectal, lung, endometrial, and numerous other cancers. However, the first-generation drugs targeting PI3Kα inhibit the wild-type and ...